SKYE BIOSCIENCE INC (SKYE) Stock Price, Quote, News and Overview
NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD
SKYE Quote, Performance and Key Statistics
1.9
-0.17 (-8.21%)
The current stock price of SKYE is 1.9 USD. In the past month the price increased by 4.4%. In the past year, price decreased by -84.25%.
SKYE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About SKYE
Company Profile
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Company Info
SKYE BIOSCIENCE INC
11250 El Camino Real, Suite 100
San Diego CALIFORNIA US
Employees: 11
Phone: 18584100266
SKYE BIOSCIENCE INC / SKYE FAQ
What is the stock price of SKYE BIOSCIENCE INC today?
The current stock price of SKYE is 1.9 USD. The price decreased by -8.21% in the last trading session.
What is the ticker symbol for SKYE BIOSCIENCE INC stock?
The exchange symbol of SKYE BIOSCIENCE INC is SKYE and it is listed on the Nasdaq exchange.
On which exchange is SKYE stock listed?
SKYE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SKYE BIOSCIENCE INC stock?
13 analysts have analysed SKYE and the average price target is 17.68 USD. This implies a price increase of 830.53% is expected in the next year compared to the current price of 1.9. Check the SKYE BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SKYE BIOSCIENCE INC worth?
SKYE BIOSCIENCE INC (SKYE) has a market capitalization of 58.86M USD. This makes SKYE a Micro Cap stock.
How many employees does SKYE BIOSCIENCE INC have?
SKYE BIOSCIENCE INC (SKYE) currently has 11 employees.
What are the support and resistance levels for SKYE BIOSCIENCE INC (SKYE) stock?
SKYE BIOSCIENCE INC (SKYE) has a support level at 1.81 and a resistance level at 1.98. Check the full technical report for a detailed analysis of SKYE support and resistance levels.
Should I buy SKYE BIOSCIENCE INC (SKYE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SKYE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SKYE, evaluating the profitability, health, valuation and growth aspects
- SKYE BIOSCIENCE INC (SKYE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SKYE BIOSCIENCE INC (SKYE) Sales and EPS estimates to see what analysts future expectations are.
- SKYE BIOSCIENCE INC (SKYE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SKYE BIOSCIENCE INC (SKYE) Insider and Institutional Ownership to learn about the owners and their transactions.
- SKYE BIOSCIENCE INC (SKYE) Stock Chart to make your own analysis
- SKYE BIOSCIENCE INC (SKYE) Latest news and press-releases to stay up to date.
Does SKYE BIOSCIENCE INC (SKYE) stock pay dividends?
SKYE does not pay a dividend.
When does SKYE BIOSCIENCE INC (SKYE) report earnings?
SKYE BIOSCIENCE INC (SKYE) will report earnings on 2025-08-07, after the market close.
What is the Price/Earnings (PE) ratio of SKYE BIOSCIENCE INC (SKYE)?
SKYE BIOSCIENCE INC (SKYE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.82).
What is the Short Interest ratio of SKYE BIOSCIENCE INC (SKYE) stock?
The outstanding short interest for SKYE BIOSCIENCE INC (SKYE) is 10.83% of its float. Check the ownership tab for more information on the SKYE short interest.
SKYE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SKYE. When comparing the yearly performance of all stocks, SKYE is a bad performer in the overall market: 96.58% of all stocks are doing better.
SKYE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SKYE. SKYE has a great financial health rating, but its profitability evaluates not so good.
SKYE Financial Highlights
Over the last trailing twelve months SKYE reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 86.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.51% | ||
| ROE | -38.98% | ||
| Debt/Equity | 0 |
SKYE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SKYE. The Buy consensus is the average rating of analysts ratings from 13 analysts.